1 CGP-43182 has been described as a potent inhibitor of group IIA secreted phospholipase A 2 (group IIA sPLA 2 ) activity in vitro. In rat mesangial cells, inhibition of group IIA sPLA 2 activity by CGP-43182 results in a 70% reduction of cytokine-stimulated prostaglandin E 2 biosynthesis, suggesting that group IIA sPLA 2 participates in arachidonic acid release and eicosanoid formation. Under these conditions the cytosolic phospholipase A 2 is not aected. 2 In mesangial cells, in addition to inhibition of catalytic activity, the membrane-permeant CGP-43182 completely blocked interleukin 1b (IL1b)-stimulated group IIA sPLA 2 gene expression. 3 A further action of CGP-43182 was a complete inhibition of cyclo-oxygenase-2 gene expression, resulting in a drastic reduction of prostaglandin formation in mesangial cells. 4 Moreover, CGP-43182 completely blocked IL1b-induced gene expression of the inducible nitric oxide synthase, leading to an inhibition of cytokine-stimulated nitric oxide formation. 5 In contrast, the stimulatory eect of the cell-permeant cyclic AMP-analogue, dibutyryl-cAMP, on the induction of these enzymes was not inhibited by CGP-43182. These data indicate that CGP-43182 interferes with IL1b-but not cyclic AMP-activated transcriptional regulation. 6 By studying components of the upstream transcription machinery, we observed an inhibition of NFkB activation by CGP-43182 in IL1b-treated cells. Moreover, we observed that CGP-43182 prevented the phosphorylation and proteolytic degradation of the endogenous NFkB inhibitor, IkB, a process necessary for NFkB activation. 7 From our data, we propose that CGP-43182 is a potent anti-in¯ammatory drug useful for preventing the consequences of a concerted action of cytokine-stimulated pro-in¯ammatory genes mediated by NFkB.